COMPASS Pathways Plc

37.29-0.6200-1.64%Vol 362.43K1Y Perf 29.21%
Jun 16th, 2021 16:00 DELAYED
BID37.28 ASK37.59
Open37.91 Previous Close37.91
Pre-Market- After-Market-
 - -  - -%
Target Price
68.00 
Analyst Rating
— — 0.00
Potential %
82.35 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.49B 
Earnings Rating
Price Range Ratio 52W %
37.72 
Earnings Date
13th May 2021

Today's Price Range

35.5538.99

52W Range

22.5161.69

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
-6.02%
1 Month
6.79%
3 Months
-4.99%
6 Months
-34.57%
1 Year
29.21%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CMPS37.29-0.6200-1.64
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.49-0.3528.57
Q04 2020-0.36-0.52-44.44
Q03 2020-0.55-1.30-136.36
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.49
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume362.43K
Shares Outstanding39.93M
Trades Count6.05K
Dollar Volume15.42M
Avg. Volume425.31K
Avg. Weekly Volume335.54K
Avg. Monthly Volume402.45K
Avg. Quarterly Volume448.76K

COMPASS Pathways Plc (NASDAQ: CMPS) stock closed at 36.34 per share at the end of the most recent trading day (a -1.64% change compared to the prior day closing price) with a volume of 304.79K shares and market capitalization of 1.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 62 people. COMPASS Pathways Plc CEO is George Goldsmith.

The one-year performance of COMPASS Pathways Plc stock is 29.21%, while year-to-date (YTD) performance is -21.73%. CMPS stock has a five-year performance of %. Its 52-week range is between 22.51 and 61.69, which gives CMPS stock a 52-week price range ratio of 37.72%

COMPASS Pathways Plc currently has a PE ratio of -17.10, a price-to-book (PB) ratio of 7.59, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.87%, a ROC of -34.20% and a ROE of -34.20%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from COMPASS Pathways Plc, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.49 for the next earnings report. COMPASS Pathways Plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for COMPASS Pathways Plc is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for COMPASS Pathways Plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

COMPASS Pathways Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

COMPASS Pathways Plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.85, ATR14 : 2.11, CCI20 : 54.59, Chaikin Money Flow : 0.08, MACD : 0.81, Money Flow Index : 62.20, ROC : 7.46, RSI : 53.88, STOCH (14,3) : 59.27, STOCH RSI : 0.00, UO : 54.95, Williams %R : -40.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of COMPASS Pathways Plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

COMPASS Pathways Plc

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

CEO: George Goldsmith

Telephone:

Address: 1 Ashley Road, Altrincham WA14 2DT, Cheshire, GB

Number of employees: 62

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

0%100%

Bearish Bullish

50%50%

News

Stocktwits